Therefore, it can be assumed, that in the case of EC313, the combination of clear but dose-dependent limited PR-agonistic and moderate but significant PR-antagonistic activities can explain the superiority of this compound in the clinically relevant models for endometriosis and fibroids using humane xenografts. The gene discussed is PGR; the disease is endometriosis.